BTG plc: Directorate Change Amendment

BTG plc: Directorate Change Amendment

BTG plc: Directorate Change Amendment

London, UK, 14 February 2012: BTG plc (LSE: BGC), the specialist healthcare company, announces that Rolf Soderstrom will no longer be leaving the company at the end of March and will continue in his role as Chief Financial Officer.

Louise Makin, BTG’s CEO, commented: “The Board is delighted that Rolf has chosen to stay at BTG. He has been a core part of the team and we look forward to his ongoing financial leadership as we continue to build our business.”

Rolf Soderstrom added: “Having been part of the team that has transformed BTG into a sizeable and successful international business, I have decided that I want to continue to help the company deliver on its growth strategy. Accordingly, I am very pleased to commit my future to BTG, which is at an exciting stage in its development.”

There are no additional disclosures required under UKLA listing rules.

About BTG
BTG is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The company is seeking to acquire new products to develop and market to specialist physicians, and is building a sustainable business financed by revenues from sales of its own marketed products and from royalties and milestone payments on partnered products.

For further information contact:

BTG
Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530605

Rolf Soderstrom, Chief Financial Officer
+44 (0)20 7575 0000

FTI Consulting
Ben Atwell
+44 (0)20 7831 3113

Back to press releases